InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（14 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
14
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Kakkis Emil d, 首席执行官. Director active across 1 company, notably Ultragenyx Pharmaceutical Inc.. In total, 24 filings have been logged. Breakdown: 0 buy · 14 sells. Total volume traded: €8.5m. History available since 3 May 2021. The latest transaction was disclosed on 16 April 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Kakkis Emil d
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报24 总计
76,745 股0Common StockSEC:0001193125-26-164308:0
71,177 股0Common StockSEC:0001193125-26-089278:0
43,268 股0Common StockSEC:0000950170-25-032779:0
11,727 股@ US$42.233.8% 占其流量Common StockSEC:0000950170-24-141485:0
20,000 股0Common StockSEC:0000950170-24-135521:0
20,000 股@ US$55.858.1% 占其流量Common StockSEC:0000950170-24-103811:0
20,000 股@ US$50.177.4% 占其流量Common StockSEC:0000950170-24-092608:0
38,428 股0Common StockSEC:0000950170-24-026625:0
30,000 股@ US$45.0010.1% 占其流量Common StockSEC:0001209191-24-002989:0
30,000 股@ US$47.8710.4% 占其流量Common StockSEC:0001209191-24-000071:0
47,853 股@ US$6.862.5% 占其流量Common StockSEC:0001209191-23-053351:0
8,716 股0Common StockSEC:0001209191-23-016041:0
19,582 股@ US$45.576.7% 占其流量Common StockSEC:0001209191-23-000276:0
12,162 股@ US$67.370.030% mcap11.5% 占其流量Common StockSEC:0001209191-22-015799:0
853 股@ US$81.000.6% 占其流量Common StockSEC:0001209191-21-060749:0
852 股@ US$115.710.8% 占其流量Common StockSEC:0001209191-21-031383:0
30,000 股@ US$107.8027.8% 占其流量Common StockSEC:0001209191-21-030211:0
2,837 股Common StockSEC:0001562180-16-001158:0
5,465 股Common StockSEC:0001562180-16-001158:1
3,600 股Common StockSEC:0001562180-16-001158:2
2,600 股Common StockSEC:0001562180-16-001158:3
2,191 股Common StockSEC:0001562180-16-001158:4
2,702 股Common StockSEC:0001562180-16-001158:5
605 股Common StockSEC:0001562180-16-001158:6
24 条申报中的 24 条
About Kakkis Emil d
KAKKIS EMIL D is President and CEO at Ultragenyx Pharmaceutical Inc. He has 24 filings in total, and across the sampled recent filings, sells total 8474976 EUR, with a date range from 2016-01-04 to 2026-04-20.
